Special Report: KRAS Finding Changes Oncology Practice But Poses Profound Regulatory Dilemma
FDA Concerned About Data-Dredging In Drug-Diagnostic Applications
Government Offers Two Approval Standards For Assays: CLIA, FDA
FDA Ponders Standards For “Retrospective Prospective” Studies
ODAC Discussion: NCI’s Richard Simon Cautions About Rules Of Thumb
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore









